DecisionHealth, DecisionHealth - 2006 Issue 6 (June)
Immune globulin payments to rise July 1 as ASP changes
Subscribe or sign in to view the full article.
Article Overview
This premium article reviews CMS’s July changes to average sales price-based payments for Medicare Part B drugs. It focuses on intravenous immune globulin payment updates, related supplemental administration payment context, and a utilization-based list of drugs with notable payment increases and decreases. It is intended for coders, billers, and reimbursement staff who track Part B drug payment updates and drug administration billing trends.
Why This Topic Matters
CMS payment updates can affect Medicare Part B drug reimbursement and practice revenue, especially for high-volume administered drugs. The article helps readers identify which drug payments changed and understand the broader ASP update context.
What You Will Learn
- How CMS July ASP updates affect Medicare Part B drug payments
- Which IVIG payment categories are discussed in the article
- Which billed drugs experienced notable payment increases or decreases
- How the article frames ASP pricing changes and utilization trends
Who Should Read This
- Medical coders
- Medical billers
- Practice managers
- Reimbursement specialists
- Oncology infusion billing staff
- Part B drug billing staff
Codes Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com